CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Citoxlab for €448 million in cash (approximately $510 million), a transaction completed in April 2019, structured as all cash.
Citoxlab operates in Discovery and Safety Assessment (DSA), is based in France / Europe and North America. Citoxlab was a non-clinical CRO providing safety assessment and related services, with operations across Europe and North America, founded over 50 years prior.
Citoxlab would expand and solidify Charles River's position as the leading global early-stage CRO by expanding its scientific portfolio and geographic footprint, which would enhance the Company's ability to partner with clients across the drug discovery and development continuum.
Expected non-GAAP EPS accretion of approximately $0.15 in 2019 and at least $0.35 in 2020 Discovery and Safety Assessment (DSA) segment
The proposed acquisition of Citoxlab would expand and solidify Charles River's position as the leading global early-stage CRO by expanding its scientific portfolio and geographic footprint.James C. Foster, Chairman, President and Chief Executive Officer, Charles River Laboratories
Advisory firms were not disclosed for this transaction.